Considering the limited knowledge surrounding TRPM8 in cancer, we used multi-database Pan-Cancer analysis to investigate this question, in terms of the TME, genetic changes, prognosis, the tumor mutational burden (TMB), drug sensitivities, and microsatellite instability (MSI), especially in relation to immune genes, neoantigens, and checkpoints, in 33 cancer types. This evidence concerns the gene TRPM8 and neoplasm.